Danaher Corporation (DHR) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated January 12, 2026, serves as a current report for Danaher Corporation. The filing was issued in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference on January 13, 2026. The report focuses on the Company's estimated financial performance for the fourth quarter of 2025 and provides estimated performance data for the full year 2025.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a conduit to incorporate by reference a press release (Exhibit 99.1) and presentation slides (Exhibit 99.1PRE) which contain the actual estimated financial figures. The filing lists the following securities registered under Section 12(b) of the Exchange Act:
- Common stock, $0.01 par value (Symbol: DHR)
- 0.200% Senior Notes due 2026
- 2.100% Senior Notes due 2026
- 1.200% Senior Notes due 2027
- 0.450% Senior Notes due 2028
- 2.500% Senior Notes due 2030
- 0.750% Senior Notes due 2031
- 1.350% Senior Notes due 2039
- 1.800% Senior Notes due 2049
Material Changes and Guidance
The filing does not detail specific material changes, year-over-year comparisons, or management commentary within the text itself. It explicitly states that the presentation slides contain information regarding estimated financial performance for 2025. The filing includes a standard disclaimer that the presentation slides are not deemed "filed" for purposes of Section 18 of the Exchange Act unless expressly incorporated by specific reference in another filing.
Investor Verification Checklist
- Review Exhibit 99.1: Verify the specific estimated revenue and earnings per share for Q4 2025 and full-year 2025 in the attached press release.
- Review Exhibit 99.1PRE: Examine the presentation slides for detailed segment performance, margin guidance, and capital allocation plans.
- Confirm Debt Obligations: Note the maturity dates of the various Senior Notes listed, particularly those due in 2026.
- Check for Forward-Looking Statements: Ensure any guidance provided in the referenced exhibits is understood as forward-looking and subject to risks and uncertainties.